Biologics growth prompts IMB cold-chain distribution guidance
The Irish Medicines Board (IMB) has published guidance for cold-chain storage and transport of APIs and finished products.
Pipeline growth & price rises encouraging signs for CROs
A year-on-year increase in active drug development projects and improving pricing will drive business to CROs, a survey found.
Dong-A and Meiji Seika to build biosimilars plant
South Korean drugmaker Dong-A and Japan’s Meiji Seika Pharma will build a biosimilars plant in a bid to target the global Ab-based drug market.
AstraZeneca takes its bioinformatics capabilities to Russia
AstraZeneca is will build a center for bioinformatics and predictive medicine in St.Petersburg, Russia by the end of 2011.
EMA OK for second Shire Replagal plant
Shire has received European Medicines Agency (EMA) approval for a new US plant, doubling purification capacity for its Fabry disease drug Replagal.
BioMarin to buy Pfizer’s Shanbally biologics plant
BioMarin will buy Pfizer’s biologics manufacturing plant in Shanbally, Cork, Ireland to add production capacity for its candidate mucopolysaccharidosis treatment.
Shire to enter regenerative meds with Advanced BioHealing buy
UK-based drugmaker Shire has unveiled plans to buy Advanced BioHealing (ABH) citing the lack of generic competition in the regenerative medicines sector as a factor.
WSF report claims 'brighter decade lies ahead' for biotech sector
World Street Fundamentals (WSF), the financial research specialist, has released two industry reports highlighting the mixed fortunes of biotech firms Biodel and MannKind, but claims a “brighter decade” lies ahead for the biotech sector.
Amgen buying Irish plant from Pfizer
Amgen will buy a manufacturing facility in Ireland from US drug giant Pfizer, securing the site’s workforce.
Fujifilm acquires Merck BioManufacturing Network
Tokyo, Japan-based digital imaging specialist, Fujifilm, has agreed a deal to buy US drug giant Merck and Co's BioManufacturing Network, including two biotech manufacturing plants.
Followed the news in 2010? Then test your knowledge of biopharm in 2010 against colleagues, peers and our community of readers in our exclusive map-based quiz.
Anti-fake readiness a factor for emerging biotech buyers
Biopharm are increasingly assessing the threat counterfeiting and diversion pose to emerging biotechs when planning an acquisition, according to a white paper.
Puerto Rico’s tax cuts to “hinder” offshore biopharma firms
PhRMA says a new Puerto Rico law to tax offshore manufacturers will “dramatically hinder” biopharma companies.
Sanofi launches hostile Genzyme bid; Pfizer close on Uplyso Brazil deal
French drugmaker Sanofi Aventis has tabled an $18.5m, $69 per share, hostile takeover bid for Genzyme after failing to secure an amicable acquisition.
GSK taps Lonza for bio plant knowledge; sells R&D site to Galapagos
GSK will work with Lonza on the development of a UK biomanufacturing plant as part of a new MAb manufacturing contract announced today.
Genzyme rejects Sanofi’s $18.5bn bid; IPT looks at biotech’s turbulent 18-months
Genzyme has rejected Sanofi-Aventis' $18.5bn (€14.5bn) takeover bid, describing it as offering no improvement in price on the previous proposal and failing “to establish a basis for engagement.”
Biologics market worth $158bn by 2015, new report
Improving safety and efficacy coupled with drug industry desire for “stronger” patents will drive growth of the biologics sector over the next five years, according to new research.
Imclone closes US Erbitux plant
Imclone has closed the manufacturing facility in Branchburg, New Jersey where it produces the cancer drug Erbitux, according to reports in the US media.
Watson buys Eden Biodesign
US generics group Watson Pharmaceuticals has bought UK contract biomanufacturing specialist Eden Biodesign.
Merck & Co to buy Avecia Biologics
US drug major Merck & Co will buy into the UK's contract biologics manufacturing sector with the acquisition of Tees Valley-based Avecia Biologics.
How successful was the BioPh conference in Madrid? in-PharmaTechnologist asked key players attending the inaugural event.
ACRO wants trials for most biosimilars
ACRO says while a 12-year exclusivity period for innovative drugs is important for R&D, US legislation should include rules on trials for biosimilars
Dispatches from CPhI
SAFC Pharma has added extra viral and biologics capacity at its California plant in a $12m project that allows it to take projects from the lab to commercial scale.
Roche buys Lonza’s Singapore biologics plant
Basel-headquartered Roche has paid fellow Swiss firm Lonza $290m (€203m) for its Singapore biologics plant in a bid to secure long-term manufacturing capacity for biotech cancer drugs.
Pfizer inaugurates new $214m Swedish biotech plant
Pfizer’s new $214.8 million (€150m) biotechnology facility in Strangnas, Sweden was inaugurated yesterday, securing the country’s future in the company’s manufacturing network according to global manufacturing president Natale Ricciardi.
OSI leaves Long Island after "failing to make biotech work"
US biotechnology group OSI Pharmaceuticals will move HQ to a facility in Greenburgh, New York due, according to observers, to the high cost of land at its current base in Long Island.
MJ Biopharm GMP breach prompts number of recalls
Novartis and Jubilant Organosys are among several companies forced to recall generic drugs after manufacturing operations at their shared CMO, India’s MJ Biopharm, were found to be in breach of GMP guidelines.
Bio drugs to dominate top ten list by 2014
Seven of the top ten drugs will be biopharmaceuticals by 2014 according to sector analysts Evaluate Pharma.
in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.
HEM Pierre Vimont, Ambassador of France to the US, was at BIO 2009 talking about the measures his nation have taken to attract biotechs, including the introduction of the "most favourable R&D tax in Europe".
Hospira calls time on US biogenerics delays
Drug delivery specialist Hospira has set up a “biologics clock” that counts the amount spent on cell culture-derived medications in the US in a bid to highlight the potential savings greater use of generics could provide.
MassBIO reflects on difficulties attracting biomanufacturing
Massachusetts Biotechnology Council’s (MBC) 2015 strategic plan has outlined the difficulties the state faces in attracting biomanufacturing and called for increased focus on R&D.
Elan cuts jobs, shelves biofacility
Faced with a tougher operating environment, Irish drugmaker Elan has decided to slash staff numbers by 230 – or around 14 per cent of its total workforce – shelve the construction of a new biologics manufacturing facility and shutter fill-and-finish capacity...
Bioceros joins PER.C6 network as only EU cell generation partner
Crucell and DSM Biologics have added fellow Dutch firm Bioceros to the PER.C6 vendor network to provide manufacturing and support capacity in line with increased demand for the cell line.
Biological E’s new vaccine campus inaugurated
Dr Rajashekar Reddy, chief minister of Andhra Pradesh, India presided over the inauguration ceremony for Biological E’s new INR3bn ($61m) vaccine and biopharmaceuticals manufacturing campus.
Late last week the US Department of Health and Human Services (HHS) awarded Novartis a $490m contract to continue work on its cell-culture influenza vaccine plant in Holly Springs, North Carolina, US. in-PharmaTechnologist spoke with Novartis spokesman...
Novartis gets $487m for US cell culture flu vac plant
Novartis will receive a further $487m (€366m) from the US HHS for its cell-culture flu vaccine plant in Holly Springs, North Carolina.
Should the FDA stare at transgenic goats?
Positive noises from an FDA panel on GTC Biotherapeutics’ recombinant antithrombin ATryn may further the use of transgenic animals for drug production but should the manufacturing process rather than the drug’s safety be our prime concern?
Siga poised for trials as US focuses on bio-terror
The completion of trial batches of Siga Technologies’ smallpox treatment ST-246 could not have been better timed following as it does the recomendation that the Obama government raise the threat of bio-terror up its list of concerns.
Biotech goes cap in hand to government
Biotech bodies from around the globe have been calling on their respective governments to provide stimulus packages to compensate for the current difficulties in obtaining credit.
Elan cuts staff and offices as Tysabri wavers
Irish drugmaker Elan, which recently dropped plans to sell its Elan Drug Technologies operation, has announced job cuts and the closure of offices in a bid to save cash.
Roundtable discusses creating a biogeneric pathway
The challenges in establishing a regulatory pathway for biogenerics were discussed at a recent FTC roundtable, with a FDA official saying in most cases it will be “impossible” to establish that the APIs are identical.
Enzon biotech sale under threat
The possible sell-off of Enzon Pharmaceuticals’ biotechnology drugs business has come under fire by one of the firm’s shareholders, DellaCamera Capital Management, which says it is opposed to the move.
Taiwan’s biotech statute continues to attract global players
Taiwan’s efforts to position itself as a major biotechnology hub received a further boost today with the opening of Merck KGaA’s dedicated technology training centre in Xizhi City, Taipei County.
Abraxis and ProMetic target US biopharma market
Abraxis has licensed rights to use ProMetic’s protein technology in the development of four new biopharmaceuticals that it hopes will generate around $600m (€422.5m) in US sales.
Vaccine sales help Crucell cut Q2 loss
An increase in the sale of vaccines such as Quinvaxem and Epaxal, helped Dutch drugmaker Crucell reduce its loss some 56 per cent to €7.9m ($12.5m) in the second quarter.
Lonza to co-develop Novartis biologics
Lonza is to co-develop and manufacture Novartis' biological pipeline as part of a long term strategic partnership that has been struck between the companies.
Invitrogen to buy Applied Biosystems for $6.7bn
Invitrogen plans to cement its place as one of the world's largest
suppliers of analysis tools and reagents for the life science and
pharmaceutical industries by acquiring Applied Biosystems (ABI).
FDA gives guidance on biologics-producing spore-forming microbes
The US Food and Drug Administration (FDA) has released new
recommendations for manufacturers of biologics using spore-forming
J&J 'concerned' as Sandoz gets biosimilar EU approval
J&J has expressed its concern over patient safety as Novartis'
subsidiary Sandoz has received the green light from the European
Commission to launch the first epoetin alfa biosimilar on the EU